来自MSN1 个月
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene ...
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million. Bluebird makes three gene therapies: Zynteglo for beta thalassemia, Lyfgenia for sickle cell ...
NBC Washington1 个月
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene ...
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday, marking the end of the Bluebird's fall from the one of the buzziest ...